Last updated on June 2019
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
Brief description of study
Open label, single arm, multicenter phase II trial.
Detailed Study Description
Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group.
PREVENE (PREemptive VENEtoclax) trial.
Clinical Study Identifier: NCT03766763
